NO971566L - Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF - Google Patents

Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF

Info

Publication number: NO971566L
Authority: NO; Norway
Prior art keywords: kgf; diabetes mellitus; treating diabetes; mammals; pharmaceutical compositions
Prior art date: 1994-10-13

Application number

NO971566A

Other languages

English (en)

Norwegian (no)

Other versions

NO971566D0 (no

Inventor

Sharon Lea Aukerman

Glenn Francis Pierce

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-10-13

Filing date

1997-04-04

Publication date

1997-04-14

1997-04-04 Application filed by Amgen Inc filed Critical Amgen Inc

1997-04-04 Publication of NO971566D0 publication Critical patent/NO971566D0/no

1997-04-14 Publication of NO971566L publication Critical patent/NO971566L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Immunology (AREA)
Hematology (AREA)
Obesity (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Emergency Medicine (AREA)
Zoology (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO971566A 1994-10-13 1997-04-04 Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF NO971566L (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US32334094A	1994-10-13	1994-10-13
US32347594A	1994-10-13	1994-10-13
US48782595A	1995-06-07	1995-06-07
PCT/IB1995/000992 WO1996011950A1 (en)	1994-10-13	1995-10-12	Method of treating diabetes mellitus using kgf

Publications (2)

Publication Number	Publication Date
NO971566D0 NO971566D0 (no)	1997-04-04
NO971566L true NO971566L (no)	1997-04-14

Family

ID=27406268

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO971566A NO971566L (no)	1994-10-13	1997-04-04	Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF
NO19971568A NO318761B1 (no)	1994-10-13	1997-04-04	Polypeptidanalog til nativ keratinocyttvekstfaktor kalt "KGF", farmasoytisk formulering, rekombinant nukleinsyremolekyl, biologisk funksjonell vektor, prokaryot eller eukaryot vertscelle, fremgangsmate for fremstilling av en analog av KGF, anvendelse av en effektiv mengde av analogen av KGF i folge oppfinnelsen, eller deltaN23 for fremstilling av et medikament for stimulering av produksjon av ikke-fibroblastepitelceller, in vitro fremgangsmate for stimulering av produksjon av ikke-fibroblastepitelceller samt sett.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO19971568A NO318761B1 (no)	1994-10-13	1997-04-04	Polypeptidanalog til nativ keratinocyttvekstfaktor kalt "KGF", farmasoytisk formulering, rekombinant nukleinsyremolekyl, biologisk funksjonell vektor, prokaryot eller eukaryot vertscelle, fremgangsmate for fremstilling av en analog av KGF, anvendelse av en effektiv mengde av analogen av KGF i folge oppfinnelsen, eller deltaN23 for fremstilling av et medikament for stimulering av produksjon av ikke-fibroblastepitelceller, in vitro fremgangsmate for stimulering av produksjon av ikke-fibroblastepitelceller samt sett.

Country Status (23)

Country	Link
EP (2)	EP0804479B1 (pt)
JP (2)	JP4216329B2 (pt)
KR (1)	KR100278597B1 (pt)
CN (1)	CN1168678A (pt)
AT (2)	ATE237633T1 (pt)
AU (1)	AU3707795A (pt)
BG (2)	BG101392A (pt)
BR (2)	BR9509329A (pt)
CA (2)	CA2201940C (pt)
CZ (3)	CZ297329B6 (pt)
DE (2)	DE69535264T2 (pt)
DK (2)	DK0804479T3 (pt)
EE (2)	EE9700225A (pt)
ES (2)	ES2196082T3 (pt)
FI (2)	FI971420A0 (pt)
HU (2)	HUT78050A (pt)
NO (2)	NO971566L (pt)
NZ (2)	NZ505502A (pt)
PL (2)	PL320484A1 (pt)
PT (2)	PT785948E (pt)
SI (2)	SI0785948T1 (pt)
SK (2)	SK284534B6 (pt)
WO (2)	WO1996011949A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GEP20022681B (en)	1989-01-31	2002-04-25	Aaronson Us Stuart A	Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth
US7084119B2 (en)	1993-06-29	2006-08-01	Chiron Corporation	Truncated keratinocyte growth factor (KGF) having increased biological activity
DK0706563T3 (da)	1993-06-29	2005-01-31	Chiron Corp	Afkortet keratonocyt-vækstfaktor (KGF) med foröget biologisk aktivetet
PT785949E (pt) *	1994-10-13	2003-09-30	Amgen Inc	Metodo para purificar factores de crescimento de queratinocitos
US6077692A (en)	1995-02-14	2000-06-20	Human Genome Sciences, Inc.	Keratinocyte growth factor-2
US6693077B1 (en)	1995-02-14	2004-02-17	Human Genome Sciences, Inc.	Keratinocyte growth factor-2
US7232667B2 (en)	1995-02-14	2007-06-19	Human Genome Sciences, Inc.	Keratinocyte growth factor-2 polynucleotides
DK0822943T3 (da) *	1995-04-27	1999-11-29	Cooperatie Cosun U A	Inulinderivater
SI0935652T1 (en) *	1996-10-15	2004-06-30	Amgen Inc.	Keratinocyte growth factor-2 products
US6743422B1 (en)	1996-10-15	2004-06-01	Amgen, Inc.	Keratinocyte growth factor-2 products
ES2218666T3 (es) *	1996-10-15	2004-11-16	Amgen Inc.,	Producto a base del factor de crecimiento de queratinocitos-2 (kggf-2).
US7153943B2 (en)	1997-07-14	2006-12-26	Bolder Biotechnology, Inc.	Derivatives of growth hormone and related proteins, and methods of use thereof
ES2297889T3 (es)	1997-07-14	2008-05-01	Bolder Biotechnology, Inc.	Derivados de hormona de crecimiento y proteinas relacionadas.
US20080076706A1 (en)	1997-07-14	2008-03-27	Bolder Biotechnology, Inc.	Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7495087B2 (en)	1997-07-14	2009-02-24	Bolder Biotechnology, Inc.	Cysteine muteins in the C-D loop of human interleukin-11
US6869927B1 (en)	1997-12-22	2005-03-22	Human Genome Sciences, Inc.	Keratinocyte growth factor-2 formulations
EP1041996A4 (en)	1997-12-22	2003-05-14	Human Genome Sciences Inc	KERATINOCYTE GROWTH FACTOR-2 FORMULATIONS
US6242666B1 (en)	1998-12-16	2001-06-05	The Scripps Research Institute	Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
JP2002534119A (ja) *	1999-01-14	2002-10-15	ボルダーバイオテクノロジー，インコーポレイテッド	自由システイン残基を有するタンパク質の生産方法
US8288126B2 (en)	1999-01-14	2012-10-16	Bolder Biotechnology, Inc.	Methods for making proteins containing free cysteine residues
US6248725B1 (en)	1999-02-23	2001-06-19	Amgen, Inc.	Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
MXPA03006988A (es) *	2001-02-06	2003-11-18	Merck Patent Gmbh	Factor de crecimiento de queratinocitos (kgf) modificado con inmunogenicidad reducida.
AU2007214362B2 (en) *	2001-08-21	2009-11-26	Novartis Vaccines And Diagnostics, Inc.	KGF polypeptide compositions
AU2002326742B2 (en) *	2001-08-21	2007-05-31	Novartis Vaccines And Diagnostics, Inc.	KGF polypeptide compositions
EP1827483B1 (en)	2004-12-15	2014-07-02	Swedish Orphan Biovitrum AB (publ)	Therapeutic formulations of keratinocyte growth factor
CN102242124B (zh) *	2010-05-10	2013-05-22	齐鲁制药有限公司	改造的角化细胞生长因子基因及其在酵母中的表达
KR102440312B1 (ko) *	2020-08-28	2022-09-05	한국해양과학기술원	온도안정성을 향상시킨 fgf7 폴리펩타이드 및 그 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4959314A (en) *	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
JPH01137994A (ja) *	1987-08-10	1989-05-30	Shionogi & Co Ltd	ｒｅｇ蛋白質
US5145225A (en) *	1988-07-27	1992-09-08	Muller George M	Carpet stretcher
GEP20022681B (en) *	1989-01-31	2002-04-25	Aaronson Us Stuart A	Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth
JP3303211B2 (ja) *	1991-04-26	2002-07-15	武田薬品工業株式会社	ｂＦＧＦムテインおよびその製造法
IL109122A (en) *	1993-03-26	2004-07-25	Amgen Inc	Use of products from a keratinocytic growth factor for the preparation of medicinal preparations
US5348563A (en) *	1993-06-29	1994-09-20	Honeywell Inc.	Air purifying apparatus
DK0706563T3 (da) *	1993-06-29	2005-01-31	Chiron Corp	Afkortet keratonocyt-vækstfaktor (KGF) med foröget biologisk aktivetet
GB9315501D0 (en) *	1993-07-27	1993-09-08	Ici Plc	Surfactant compositions
WO1995003831A1 (en) *	1993-08-02	1995-02-09	Prizm Pharmaceuticals, Inc.	Monogenous preparations of cytotoxic conjugates

1995
- 1995-10-12 DK DK95934808T patent/DK0804479T3/da active
- 1995-10-12 CN CN95196410A patent/CN1168678A/zh active Pending
- 1995-10-12 HU HU9901071A patent/HUT78050A/hu unknown
- 1995-10-12 SI SI9530654T patent/SI0785948T1/xx unknown
- 1995-10-12 DE DE69535264T patent/DE69535264T2/de not_active Expired - Lifetime
- 1995-10-12 SI SI9530728T patent/SI0804479T1/sl unknown
- 1995-10-12 NZ NZ505502A patent/NZ505502A/en not_active IP Right Cessation
- 1995-10-12 JP JP51307796A patent/JP4216329B2/ja not_active Expired - Fee Related
- 1995-10-12 PL PL95320484A patent/PL320484A1/xx unknown
- 1995-10-12 CA CA002201940A patent/CA2201940C/en not_active Expired - Fee Related
- 1995-10-12 DK DK95934793T patent/DK0785948T3/da active
- 1995-10-12 EP EP95934808A patent/EP0804479B1/en not_active Expired - Lifetime
- 1995-10-12 AT AT95934793T patent/ATE237633T1/de active
- 1995-10-12 CZ CZ20023953A patent/CZ297329B6/cs not_active IP Right Cessation
- 1995-10-12 PT PT95934793T patent/PT785948E/pt unknown
- 1995-10-12 EE EE9700225A patent/EE9700225A/xx unknown
- 1995-10-12 EE EE9700081A patent/EE03975B1/xx not_active IP Right Cessation
- 1995-10-12 HU HU9901255A patent/HU226168B1/hu not_active IP Right Cessation
- 1995-10-12 PT PT95934808T patent/PT804479E/pt unknown
- 1995-10-12 EP EP95934793A patent/EP0785948B1/en not_active Expired - Lifetime
- 1995-10-12 AU AU37077/95A patent/AU3707795A/en not_active Abandoned
- 1995-10-12 PL PL95319784A patent/PL182888B1/pl not_active IP Right Cessation
- 1995-10-12 JP JP51307696A patent/JP4426646B2/ja not_active Expired - Fee Related
- 1995-10-12 CZ CZ0105097A patent/CZ297328B6/cs not_active IP Right Cessation
- 1995-10-12 SK SK455-97A patent/SK284534B6/sk not_active IP Right Cessation
- 1995-10-12 WO PCT/IB1995/000971 patent/WO1996011949A2/en active IP Right Grant
- 1995-10-12 SK SK431-97A patent/SK43197A3/sk unknown
- 1995-10-12 ES ES95934793T patent/ES2196082T3/es not_active Expired - Lifetime
- 1995-10-12 ES ES95934808T patent/ES2273338T3/es not_active Expired - Lifetime
- 1995-10-12 CA CA002202075A patent/CA2202075C/en not_active Expired - Fee Related
- 1995-10-12 KR KR1019970702343A patent/KR100278597B1/ko not_active IP Right Cessation
- 1995-10-12 AT AT95934808T patent/ATE342278T1/de active
- 1995-10-12 BR BR9509329A patent/BR9509329A/pt not_active Application Discontinuation
- 1995-10-12 WO PCT/IB1995/000992 patent/WO1996011950A1/en active IP Right Grant
- 1995-10-12 DE DE69530403T patent/DE69530403T2/de not_active Expired - Lifetime
- 1995-10-12 BR BR9509269A patent/BR9509269A/pt not_active Application Discontinuation
- 1995-10-12 CZ CZ97981A patent/CZ98197A3/cs unknown
1997
- 1997-04-04 NO NO971566A patent/NO971566L/no unknown
- 1997-04-04 FI FI971420A patent/FI971420A0/fi unknown
- 1997-04-04 NO NO19971568A patent/NO318761B1/no not_active IP Right Cessation
- 1997-04-07 BG BG101392A patent/BG101392A/xx unknown
- 1997-04-11 FI FI971536A patent/FI120040B/fi not_active IP Right Cessation
- 1997-04-11 BG BG101408A patent/BG63167B1/bg unknown
1999
- 1999-04-09 NZ NZ335109A patent/NZ335109A/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
PT804479E (pt)	2007-02-28
NO971568L (no)	1997-06-12
DK0804479T3 (da)	2007-01-29
BR9509269A (pt)	1997-12-23
AU3708395A (en)	1996-05-06
DE69530403T2 (de)	2003-10-30
HUT78050A (hu)	1999-07-28
ATE342278T1 (de)	2006-11-15
DK0785948T3 (da)	2003-08-04
CA2201940A1 (en)	1996-04-25
HU226168B1 (en)	2008-05-28
SK43197A3 (en)	1999-03-12
FI971536A0 (fi)	1997-04-11
NO318761B1 (no)	2005-05-02
CZ105097A3 (cs)	1998-10-14
BG101392A (en)	1997-10-31
CZ98197A3 (cs)	1998-11-11
PL319784A1 (en)	1997-08-18
CA2202075A1 (en)	1996-04-25
SI0785948T1 (en)	2003-08-31
AU681546B2 (en)	1997-08-28
ES2273338T3 (es)	2007-05-01
WO1996011950A1 (en)	1996-04-25
CZ297328B6 (cs)	2006-11-15
NZ505502A (en)	2005-01-28
DE69535264D1 (de)	2006-11-23
EE03975B1 (et)	2003-02-17
FI971536A (fi)	1997-06-09
KR100278597B1 (ko)	2001-01-15
JP4216329B2 (ja)	2009-01-28
CA2201940C (en)	2009-05-12
ES2196082T3 (es)	2003-12-16
SK284534B6 (sk)	2005-06-02
FI971420A (fi)	1997-04-04
EP0804479B1 (en)	2006-10-11
PL320484A1 (en)	1997-09-29
BR9509329A (pt)	1997-10-14
EP0785948A1 (en)	1997-07-30
JPH10507193A (ja)	1998-07-14
HUT78058A (hu)	1999-07-28
JP4426646B2 (ja)	2010-03-03
FI971420A0 (fi)	1997-04-04
CZ297329B6 (cs)	2006-11-15
DE69535264T2 (de)	2007-02-01
WO1996011949A2 (en)	1996-04-25
SI0804479T1 (sl)	2006-12-31
WO1996011949A3 (en)	1996-12-12
FI120040B (fi)	2009-06-15
EP0785948B1 (en)	2003-04-16
NO971568D0 (no)	1997-04-04
JPH10507080A (ja)	1998-07-14
SK45597A3 (en)	1999-02-11
CA2202075C (en)	2003-12-09
ATE237633T1 (de)	2003-05-15
BG63167B1 (bg)	2001-05-31
AU3707795A (en)	1996-05-06
EE9700225A (et)	1998-02-16
CN1168678A (zh)	1997-12-24
EE9700081A (et)	1997-10-15
DE69530403D1 (de)	2003-05-22
NZ335109A (en)	2000-08-25
NO971566D0 (no)	1997-04-04
PT785948E (pt)	2003-09-30
PL182888B1 (pl)	2002-03-29
BG101408A (en)	1997-12-30
EP0804479A1 (en)	1997-11-05

Publication	Publication Date	Title
NO971566L (no)	1997-04-14	Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF
AU8163398A (en)	1999-01-04	Inhibitors of alpha4beta1mediated cell adhesion
ATE190623T1 (de)	2000-04-15	Verwendung von steroiden zur inhibierung von angiogenesis
NO20056021L (no)	1999-03-15	Anvendelse av CS-866 til fremstilling av et medikament
AU2209500A (en)	2000-07-12	Inhibitors of alpha4beta1 mediated cell adhesion
MX9704050A (es)	1997-08-30	P-amidinobencilamidas de dipeptido novedosas con radicales sulfonilo o aminosulfonilo en terminal n.
NO982229L (no)	1998-07-15	Svovelholdige di-tert-butylfenol-forbindelser anvendbare som anti-inflammatoriske midler
MD960168A (ro)	1998-04-30	Metodă şi compuşi pentru tratamentul infecţiilor virale
GEP20012511B (en)	2001-08-27	Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
SE9400524L (sv)	1995-08-17	Energipreparat
ATE306278T1 (de)	2005-10-15	Behandlung von knochenleiden mit adrenomedullin
DE69110861D1 (de)	1995-08-03	Mittel zur verbesserung des kollagenmetabolismus und dessen verwendung.
AUPM836794A0 (en)	1994-10-20	Improved method and composition for the treatment of ulcers
NO984198D0 (no)	1998-09-11	Fremgangsmåte for behandling av aggresjon
AU7583796A (en)	1997-06-19	Improvements relating to the use of treated lignocellulosic materials
UA15363A (uk)	1997-06-30	Засіб для лікуваhhя відкритих пошкоджеhь
AU3597695A (en)	1996-04-09	Improved method and composition for the treatment of ulcers
AUPN733195A0 (en)	1996-01-25	Improved method and composition for the treatment of ulcers